Pharmaceutical Executive
Washington, DC-Pro-life advocates recently dropped a lawsuit challenging the promotion of abortifacient RU-486 through ads sponsored by the National Abortion Federation. The suit charged NAF with using deceptive advertising by promoting Mifepristone as safe in several national magazines, including Self, Cosmopolitan, InStyle, Vanity Fair, and People. The ads stated, "You have the freedom to choose. And now, you have another safe abortion choice."
Washington, DC-Pro-life advocates recently dropped a lawsuit challenging the promotion of abortifacient RU-486 through ads sponsored by the National Abortion Federation. The suit charged NAF with using deceptive advertising by promoting Mifepristone as safe in several national magazines, including Self, Cosmopolitan, InStyle, Vanity Fair, and People. The ads stated, "You have the freedom to choose. And now, you have another safe abortion choice."
The suit filed in Chicago circuit court last August claimed the ads should describe side effects from the abortion pill, as required by Illinois law. The plaintiffs backed out in January, saying that only state attorneys general or the Federal Trade Commission had the resources to carry on the fight. They also cited personal plans to be involved in political races in Illinois in coming months.
NAF executive director Vicki Saporta claimed victory against "this frivolous lawsuit" and says the withdrawal indicates it "had absolutely no merit." She says the plaintiffs brought the case "solely to advance their antichoice agenda" and that NAF's public education campaign provides accurate information about the product. Many clinics and doctors have been reluctant to prescribe Mifepristone for fear of lawsuits or protests, and the NAF campaign was an effort to build consumer demand.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.